BRIEF-4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc.

FDMT

0.00

July 18 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O:

  • 4DMT ANNOUNCES POSITIVE 2-YEAR DATA FROM PRISM PHASE 2B CLINICAL TRIAL IN A BROAD WET AMD POPULATION

  • 4D MOLECULAR THERAPEUTICS - 4D-150 CONTINUES TO BE WELL TOLERATED WITH NO NEW SAFETY FINDINGS

Source text: ID:nGNX80nHf5

Further company coverage: FDMT.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.